Post-Doc- Design, synthesis and evaluation of prodrug conjugates for sustained-release drug delivery-ON-352

Desired discipline(s): Chemistry, Natural Sciences
Company: Ripple Therapeutics Corporation
Project Length: 6 months to 1 year
Preferred start date: As soon as possible.
Language requirement: English
Location(s): Toronto, ON, Canada; Mississauga, ON, Canada; Canada
No. of positions: 1
Search across Mitacs’ international networks - check this box if you’d also like to receive profiles of researchers based outside of Canada: 
No

About the company: 

Ripple Therapeutics is the therapeutics/drug delivery spin out of Interface Biologics, Inc. (IBI). Our lead product (IBE-814 IVT) is a fully degradable intravitreal (IVT) dexamethasone prodrug implant targeting posterior inflammatory eye diseases. Our target product profile is zero-order drug release for 6-9 months with a 30G needle and 1/10th the loading of the leading commercial IVT product which suggests a potential to reduce steroid related cataract and IOP AEs. Ripple has 25 employees with a dedicated 16 member R&D team made up of Chemists, Engineers and Material Scientists. Our leaders are experienced in managing industries through various stages of growth. 

Please describe the project.: 

Controlled drug delivery has the potential to improve treatment options for numerous conditions and diseases by improving patient compliance and maintaining drug concentrations in the therapeutic window long-term thereby increasing drug efficacy while reducing undesirable side effects. The goal of Ripple Therapeutics’ (RTC) Epidel® technology is to develop prodrugs that have unique properties allowing them to be processed into implants for controlled drug delivery without the use of polymers. RTC’s first product in development is based on a dexamethasone prodrug being developed as an intravitreal implant for the treatment of patients with ocular inflammatory conditions. The goal of the proposed work is to design and synthesize novel prodrugs from different drug classes to develop new controlled release implants. The proposed drug classes cover indications where controlled delivery would significantly improve current standard of care treatment options. The candidate will use their medicinal chemistry background to design and synthesize prodrugs with different linkers to achieve different physiochemical properties with drugs currently used in the treatment of these disorders. The prodrugs will be characterized for the ability to form implants and linker-drug chemistry optimization will be made to down-select candidates to move forward to product development. The post-doctoral fellow will work under the supervision of Dr. Patrick Gunning from the University of Toronto Mississauga.

Required expertise/skills: 

  • Ph.D in Organic Chemistry or Medicinal Chemistry
  • Strong practical experience in organic synthesis and purification techniques
  • Strong practical experience in analytical techniques including NMR, HPLC, MS, LC-MS, IR, DSC, XRD
  • Working knowledge of material testing
  • Strong problem solving ability and creativity while working in a well-organized and logical manner; 
  • Strong collaboration and interpersonal skills, and communication skills;
  • Flexible, with an ability to balance priorities and adhere to timelines